Factorial design applied to the optimization of lipid composition of topical antiherpetic nanoemulsions containing isoflavone genistein

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 4737-4747

  Argenta, Débora Fretes ^a   de Mattos, Cristiane Bastos ^a   Misturini, Fabíola Dallarosa ^a   Koester, Leticia Scherer ^a   Bassani, Valquiria Linck ^a   Maria Oliveira SimõEs, Cláudia ^b   Teixeira, Helder Ferreira ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Antiherpetic activity; Cationic nanoemulsions; Phospholipids; Skin retention

Indexed keywords

CASTOR OIL; DIOLEOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; GENISTEIN; ISOFLAVONE; MYRISTIC ACID ISOPROPYL ESTER; OLEYLAMINE; SURFACTANT; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; EMULSION; NANOPARTICLE; NILE RED; OXAZINE DERIVATIVE; PHOSPHOLIPID;

ANIMAL CELL; ANIMAL TISSUE; ANTIHERPETIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CHEMICAL PARAMETERS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RETENTION; DRUG SOLUBILITY; FACTORIAL DESIGN; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1 (STRAIN KOS); HERPES SIMPLEX VIRUS 22 (STRAIN 333); IC50; IN VITRO STUDY; LIMIT OF QUANTITATION; LIPID COMPOSITION; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; PROCESS OPTIMIZATION; SKIN PERMEABILITY; SWINE; VIRUS PLAQUE; ANIMAL; CHEMISTRY; DRUG EFFECTS; EMULSION; HERPES SIMPLEX VIRUS 1; MEDICINAL CHEMISTRY; METHODOLOGY; PHARMACOLOGY; PIG; SKIN; SKIN ABSORPTION;

ANIMALS; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; EMULSIONS; GENISTEIN; HERPESVIRUS 1, HUMAN; NANOPARTICLES; OXAZINES; PARTICLE SIZE; PHOSPHOLIPIDS; RESEARCH DESIGN; SKIN; SKIN ABSORPTION; SWINE;

EID: 84907882650     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S67732     Document Type: Article

References (45)

1. Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral Res. 2004;61(2):73–81.
2. Simmons A. Clinical manifestations and treatment considerations of herpes simplex virus infection. J Infect Dis. 2002;186 Suppl 1:S71–S77.
3. Mundinger TA, Efferth T. Herpes simplex virus: Drug resistance and new treatment options using natural products (Review). Mol Med Rep. 2008;1(5):611–616.
4. Field HJ. Herpes simplex virus antiviral drug resistance – current trends and future prospects. J Clin Virol. 2001;21(3):261–269.
5. Chiang LC, Chiang W, Chang MY, Ng LT, Lin CC. Antiviral activity of Plantago major extracts and related compounds in vitro. Antiviral Res. 2002;55(1):53–62.
6. Zhong MG, Xiang YF, Qiu XX, Liu Z, Kitazato K, Wang YF. Natural products as a source of anti-herpes simplex virus agents. RSC Advances. 2013;3:313–328
7. Lyu SY, Rhim JY, Park WB. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch Pharm Res. 2005;28(11):1293–1301.
8. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262(12):5592–5595.
9. Andres A, Donovan SM, Kuhlenschmidt MS. Soy isoflavones and virus infections. J Nutr Biochem. 2009;20(8):563–569.
10. Yura Y, Yoshida H, Sato M. Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase. Arch Virol. 1993;132(3–4):451–461.
11. Hukkanen V, Mikola H, Nykänen M, Syrjänen S. Herpes simplex virus type 1 infection has two separate modes of spread in three-dimensional keratinocyte culture. J Gen Virol. 1999;80(Pt 8):2149–2155.
12. Elias PM, Cooper ER, Korc A, Brown BE. Percutaneous transport in relation to stratum corneum structure and lipid composition. J Invest Dermatol. 1981;76(4):297–301.
13. Swartzendruber DC, Wertz PW, Kitko DJ, Madison KC, Downing DT. Molecular models of the intercellular lipid lamellae in mammalian stratum corneum. J Invest Dermatol. 1989;92(2):251–257.
14. Kaplun-Frischoff Y, Touitou E. Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. J Pharm Sci. 1997;86(12):1394–1399.
15. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603–618.
16. Barel AO, Paye M, Maibach HI. Handbook of Cosmetic Science and Technology. 3rd ed. New York, NY: Marcel Dekker; 2009.
17. Kumar D, Aqil M, Rizwan M, Sultana Y, Ali M. Investigation of a nanoemulsion as vehicle for transdermal delivery of amlodipine. Pharmazie. 2009;64(2):80–85.
18. Harwansh RK, Patra KC, Pareta SK, Singh J, Rahman MA. Nanoemulsions as vehicles for transdermal delivery of glycyrrhizin. Braz J Pharm Sci. 2011;47(4):769–778.
19. Barakat N, Fouad E, Elmedany A. Enhancement of skin permeation and anti-inflammatory effect of indomethacin using nanoemulsuion. Lett Drug Des Discov. 2012;9(4):436–446.
20. Hoeller S, Sperger A, Valenta C. Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int J Pharm. 2009;370(1–2):181–186.
21. Gulbake A, Jain A, Jain S. Development of nanostructured lipid carrier as potential sun protectant. Nanoscience and Nanotechnology-Asia. 2012;2(2):210–216.
22. Fernández-Campos F, Clares Naveros B, López Serrano O, Alonso Merino C, Calpena Campmany AC. Evaluation of novel nystatin nanoemulsion for skin candidosis infections. Mycoses. 2013;56(1):70–81.
23. Morganti P, Ruocco E, Wolf R, Ruocco V. Percutaneous absorption and delivery systems. Clin Dermatol. 2001;19(4):489–501.
24. Montgomery DC. Design and Analysis of Experiments. 3rd ed. Somerset, NJ: John Wiley & Sons Inc; 1991.
25. Silva AP, Nunes BR, De Oliveira MC, et al. Development of topical nanoemulsions containing the isoflavone genistein. Pharmazie. 2009; 64(1):32–35.
26. de Vargas BA, Argenta DF, Borghetti G, Koester LS, Bassani VL, Teixeira HF. Validation of an LC method to determine skin retention profile of genistein from nanoemulsions incorporated in hydrogels. J Chromatogr Sci. 2012;50(2):114–118.
27. Burleson RC, Chambers TM, Wiedbrauk DL. Virology: A Laboratory Manual. San Diego, CA: Academic; 1992.
28. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1(3):1112–1116.
29. Silva IT, Costa GM, Stoco PH, Schenkel EP, Reginatto FH, Simões CM. In vitro antiherpes effects of a C-glycosylflavonoid-enriched fraction of Cecropia glaziovii Sneth. Lett Appl Microbiol. 2010;51(2):143–148.
30. Abolmaali SS, Tamaddon AM, Farvadi FS, Daneshamuz S, Moghimi H. Pharmaceutical nanoemulsions and their potential topical and transdermal applications. Iranian Journal of Pharmaceutical Sciences. 2011; 7(3):139–150
31. Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance. Int J Pharm. 2011;414(1–2):267–275.
32. Müller RH, Schmidt S, Buttle I, Akkar A, Schmitt J, Brömer S. SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm. 2004;269(2):293–302.
33. Goldberg-Cettina M, Liu P, Nightingale J, Kurihara-Bergstrom T. Enhanced transdermal delivery of estradiol in vitro using binary vehicles of isopropyl myristate and short-chain alkanols. Int J Pharm. 1995; 114(2):237–245.
34. Santos P, Watkinson AC, Hadgraft J, Lane ME. Influence of penetration enhancer on drug permeation from volatile formulations. Int J Pharm. 2012;439(1–2):260–268.
35. Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, Ma JK. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm Res. 1992;9(8): 1029–1034.
36. Eskandar NG, Simovic S, Prestidge CA. Mechanistic insight into the dermal delivery from nanoparticle-coated submicron O/W emulsions. J Pharm Sci. 2010;99(2):890–904.
37. Rabinovich-Guilatt L, Couvreur P, Lambert G, Goldstein D, Benita S, Dubernet C. Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem Phys Lipids. 2004;131(1):1–13.
38. Martini E, Fattal E, de Oliveira MC, Teixeira H. Effect of cationic lipid composition on properties of oligonucleotide/emulsion complexes: Physico-chemical and release studies. Int J Pharm. 2008;352(1–2): 280–286
39. Huang ZR, Hung CF, Lin YK, Fang JY. In vitro and in vivo evaluation of topical delivery and potential dermal use of soy isoflavones genistein and daidzein. Int J Pharm. 2008;364(1):36–44.
40. Rothwell JA, Day AJ, Morgan MR. Experimental determination of octanol-water partition coefficients of quercetin and related flavonoids. J Agric Food Chem. 2005;53(11):4355–4360.
41. Kim SY, Na YJ, Kim D, et al. Development of estimation methods of skin oxidation and evaluation of anti-oxidative effects of genistein in topical formulations. Korean J Physiol Pharmacol. 2012;16(3):205–209.
42. Kitagawa S, Inoue K, Teraoka R, Morita SY. Enhanced skin delivery of genistein and other two isoflavones by microemulsion and prevention against UV irradiation-induced erythema formation. Chem Pharm Bull (Tokyo). 2010;58(3):398–401.
43. Zampieri AL, Ferreira FS, Resende EC, et al. Biodegradable polymeric nanocapsules based on poly(DL-lactide) for genistein topical delivery: obtention, characterization and skin permeation studies. J Biomed Nanotechnol. 2013;9(3):527–534.
44. Rehman Zu, Zuhorn IS, Hoekstra D. How cationic lipids transfer nucleic acids into cells and across cellular membranes: recent advances. J Control Release. 2013;166(1):46–56.
45. Amoros M, Simões CM, Girre L, Sauvager F, Cormier M. Synergistic effect of flavones and flavonols against herpes simplex virus type 1 in cell culture. Comparison with the antiviral activity of propolis. J Nat Prod. 1992;55(12):1732–1740.